Related Experiment Videos
Combined vitamin A and E therapy prevents retinal electrophysiological deterioration in abetalipoproteinaemia
Insights
Combined vitamin A and E therapy may halt vision loss in patients with abetalipoproteinaemia. This treatment, initiated early or later in life, showed no progression of visual dysfunction in a 2-6 year follow-up study.
Area of Science:
- Ophthalmology
- Nutritional Science
- Genetics
Background:
- Abetalipoproteinaemia is a rare genetic disorder characterized by impaired absorption of dietary fats and fat-soluble vitamins.
- Patients typically present with progressive neurological and ophthalmological complications, including retinitis pigmentosa-like changes.
- Early diagnosis and intervention are crucial to mitigate long-term health consequences.
Purpose of the Study:
- To evaluate the efficacy of combined vitamin A and E supplementation in arresting the progression of visual dysfunction in patients with abetalipoproteinaemia.
- To assess the impact of therapy initiation timing on treatment outcomes.
Main Methods:
- A cohort of eight patients with confirmed abetalipoproteinaemia was studied.
- Combined vitamin A and E therapy was administered, with treatment initiation ranging from infancy to adulthood (up to 26 years of age).
- Patients were monitored for 2-6 years, with objective retinal function tests including electroretinography (ERG) and electrooculography (EOG).
Main Results:
- No progression of visual function impairment was observed in any patient following the initiation of combined vitamin A and E therapy.
- Objective retinal function tests (ERG, EOG) supported the clinical findings, indicating a stabilization of retinal function.
- The study included patients with varying ages at therapy initiation, suggesting potential benefits regardless of disease duration.
Conclusions:
- Combined vitamin A and E therapy appears to be effective in arresting retinal deterioration in patients with abetalipoproteinaemia.
- Early and potentially later initiation of this combined vitamin therapy may preserve visual function.
- This therapeutic approach offers a promising strategy for managing the ophthalmological manifestations of abetalipoproteinaemia.
Abstract:
Eight patients with abetalipoproteinaemia had the typical ocular, systemic, and laboratory findings of this disease. Combined therapy with vitamins A and E was administered, starting as early as the first day of life and as late as 26 years of age. The patients were followed up for 2-6 years. Electroretinography was undertaken in all cases and electrooculography in some. After initiation of vitamin A and E therapy no progression of disturbed visual function could be detected in any patient. These objective tests of retinal function demonstrated that the combined vitamin A and E therapy may be useful in arresting retinal deterioration in abetalipoproteinaemia.